MedTrace Logo

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

NCT05213195 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-02-12

No results posted yet for this study

Summary

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

Conditions

  • Refractory Metastatic Colorectal Cancer

Interventions

DRUG

NKG2D CAR-NK

NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Weijia Fang, MD · The First Affiliated Hospital, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05213195 on ClinicalTrials.gov